The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period.
Hyponatremia is often seen in SCLC, and is thought to be caused by the paraneoplastic syndrome SIADH. Variable results of the prognostic significance of low P-sodium (P-Na) have been reported. This study was performed to investigate the prognostic value of hyponatremia in SCLC. Data was obtained from files from 453 patients diagnosed with SCLC and treated at Odense University Hospital from 1995 to 2005 in which data on P-sodium was available. The standard chemotherapy was six cycles of carboplatin-etoposide. P-Na was <125 mEq/L in 47 patients (11%) and 126-135 mEq/L in 151 (33%), and 255 patients (56%) showed normal values. The median survival was 11.2 months in patients with normal P-Na, and 7.1 months in patients with subnormal values (p=0.0001). In a Cox multivariate analysis of the 402 patients treated with carboplatin-etoposide, hyponatremia was associated with poorer prognosis. Other independent prognostic factors included LDH, gender, age, performance status, stage, and low value of albumin. Treatment prior to year 2000 was of border line significance, while in-significant factors included hemoglobin level, WBC and alkaline phosphatase. In 61 patients with P-Na <130 mEq/L receiving two or more cycles of chemotherapy, only 15 of the 61 patients (25%) normalized the value of P-Na to 136 mEq/L or above at the time of the second cycle of chemotherapy. The patients who did not fully regain normal values of P-Na, had poorer survival compared with the patients who did in a univariate analysis (p=0.027), and in a Cox multivariate analysis. In conclusion, hyponatremia was a significant prognostic factor associated with poor prognosis and so was failure to normalize P-Na within the first two cycles of chemotherapy.
Hansen
Olfred
O
Department of Oncology, R, Odense University Hospital, DK-5000 Odense C, Denmark. olfred@dadlnet.dk
Sørensen
Peter
P
Hansen
Karin Holmskov
KH
D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis; D016190:Carboplatin / Q000008:administration & dosage; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007010:Hyponatremia; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009367:Neoplasm Staging; D010949:Plasma / Q000737:chemistry; D011379:Prognosis; D012189:Retrospective Studies; D012737:Sex Factors; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D012964:Sodium / Q000032:analysis / Q000172:deficiency; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D005047:Etoposide; D012964:Sodium; D016190:Carboplatin